CN102177180A - 烷基化半合成的糖胺聚糖醚及其制备和使用方法 - Google Patents

烷基化半合成的糖胺聚糖醚及其制备和使用方法 Download PDF

Info

Publication number
CN102177180A
CN102177180A CN2009801208979A CN200980120897A CN102177180A CN 102177180 A CN102177180 A CN 102177180A CN 2009801208979 A CN2009801208979 A CN 2009801208979A CN 200980120897 A CN200980120897 A CN 200980120897A CN 102177180 A CN102177180 A CN 102177180A
Authority
CN
China
Prior art keywords
compound
sage
hyaluronan
skin
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801208979A
Other languages
English (en)
Chinese (zh)
Inventor
G·普雷斯特维奇
J·张
T·P·肯尼蒂
N·饶
X·徐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CN102177180A publication Critical patent/CN102177180A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
CN2009801208979A 2008-04-04 2009-04-03 烷基化半合成的糖胺聚糖醚及其制备和使用方法 Pending CN102177180A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4231008P 2008-04-04 2008-04-04
US61/042310 2008-04-04
PCT/US2009/039498 WO2009124266A2 (en) 2008-04-04 2009-04-03 Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof

Publications (1)

Publication Number Publication Date
CN102177180A true CN102177180A (zh) 2011-09-07

Family

ID=41055226

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801208979A Pending CN102177180A (zh) 2008-04-04 2009-04-03 烷基化半合成的糖胺聚糖醚及其制备和使用方法

Country Status (10)

Country Link
US (5) US7855187B1 (https=)
EP (1) EP2281008B1 (https=)
JP (1) JP5758797B2 (https=)
KR (1) KR101594552B1 (https=)
CN (1) CN102177180A (https=)
AU (1) AU2009231634B2 (https=)
BR (1) BRPI0909849A2 (https=)
CA (1) CA2719666C (https=)
MX (1) MX2010010904A (https=)
WO (1) WO2009124266A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854134A (zh) * 2012-12-12 2015-08-19 索尔维特殊聚合物意大利有限公司 氟化壳聚糖衍生物
CN108350094A (zh) * 2015-11-16 2018-07-31 费迪亚医药股份公司 生产高纯度硫酸化ha的改进方法
CN111491641A (zh) * 2017-10-18 2020-08-04 格莱科米拉治疗公司 治疗慢性鼻窦炎的方法和组合物

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190691T1 (hr) 2008-03-27 2019-07-12 Purdue Research Foundation Sintetički peptidoglikani koji vezuju kolagen, priprema, i postupci upotrebe
AU2009231634B2 (en) * 2008-04-04 2014-05-15 University Of Utah Research Foundation Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
WO2011094149A1 (en) * 2010-01-26 2011-08-04 University Of Utah Research Foundation Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
CA2790682C (en) * 2010-03-03 2020-11-24 Neocutis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
US20130209531A1 (en) 2010-06-08 2013-08-15 University Of Utah Research Foundation Applications of partially and fully sulfated hyaluronan
CA2830933A1 (en) 2011-03-23 2012-09-27 University Of Utah Research Foundation Methods for treating or preventing urological inflammation
KR20140042795A (ko) * 2011-03-23 2014-04-07 유니버시티 오브 유타 리서치 파운데이션 비뇨기 염증을 치료 또는 예방하는 방법
EP3208278B1 (en) 2011-05-24 2018-10-31 Symic IP, LLC Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
JP5873319B2 (ja) * 2011-12-16 2016-03-01 株式会社コーセー メイラード反応阻害剤
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
RU2617764C2 (ru) 2011-12-19 2017-04-26 Дилафор Аб Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение
CN104411316B (zh) 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
US9688724B2 (en) 2012-05-14 2017-06-27 University Of Southern California Methods for limiting development of a skin wound
US9717752B2 (en) 2012-05-15 2017-08-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Uses of antagonists of hyaluronan signaling
WO2014144969A1 (en) 2013-03-15 2014-09-18 Purdue Research Foundation Extracellular matrix-binding synthetic peptidoglycans
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
ES2837626T3 (es) 2013-07-10 2021-07-01 Matrix Biology Inst Composiciones de hialuronano con alta elasticidad y usos de las mismas
CA2928585A1 (en) * 2013-10-22 2015-04-30 Cantex Pharmaceuticals, Inc. Methods of treating and preventing radiation damage
CA2931726C (en) 2013-11-25 2022-03-15 Deuteria Biomaterials, Llc Deuterium-enriched hyaluronan
US9637713B2 (en) 2014-01-10 2017-05-02 Lost Spirits Distillery, Llc Method for rapid maturation of distilled spirits using light and heat processes
US10947488B2 (en) 2014-01-10 2021-03-16 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light and heat processes
US9637712B2 (en) 2014-01-10 2017-05-02 Lost Spirits Distillery, Llc Method for rapid maturation of distilled spirits using light and heat processes
US10508259B2 (en) 2014-01-10 2019-12-17 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
ES2871199T3 (es) 2015-09-24 2021-10-28 Matrix Biology Inst Composiciones de hialuronano de alta elasticidad y métodos de uso de las mismas
US11337994B2 (en) 2016-09-15 2022-05-24 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
US10849914B2 (en) 2017-06-12 2020-12-01 University Of Utah Research Foundation Methods for producing chemoembolic agents for the delivery of anti-cancer agents
AU2018298224B2 (en) 2017-07-07 2024-08-15 Symic Ip, Llc Synthetic bioconjugates
CN108586574B (zh) * 2018-04-26 2019-11-12 国家海洋局第三海洋研究所 氨基葡萄糖肽类化合物及其制备方法与应用
EP3810125B1 (en) 2018-06-03 2025-07-23 Glycomira Therapeutics, Inc. Sulfated polysaccharide for use in preventing oral mucositis after exposure to ionizing radiation
CN111228653A (zh) 2018-11-13 2020-06-05 格莱科米拉治疗公司 用电离辐射加强癌症治疗的方法
KR102793214B1 (ko) 2019-01-30 2025-04-08 보오슈 앤드 롬 인코포레이팃드 가교화 중합체 망상구조물 및 이의 용도
WO2022157307A1 (en) * 2021-01-22 2022-07-28 Dsm Ip Assets B.V. Hyaluronic acid as antimicrobial agent for use on the skin
WO2022157314A1 (en) * 2021-01-22 2022-07-28 Dsm Ip Assets B.V. Hyaluronic acid for use on the skin
CN112972490B (zh) * 2021-03-04 2022-02-18 中国人民解放军军事科学院军事医学研究院 透明质酸在用于制备预防或治疗铁死亡相关疾病的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199687A1 (en) * 2002-04-11 2003-10-23 Manssur Yalpani Biocompatible materials and probes
WO2007006403A2 (en) * 2005-07-07 2007-01-18 Fidia Advanced Biopolymers S.R.L. Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2599172A (en) 1948-11-29 1952-06-03 Searle & Co Sulfuric acid esters of hyaluronic acid and processes for the production thereof
US4240163A (en) * 1979-01-31 1980-12-23 Galin Miles A Medicament coated intraocular lens
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
FR2584728B1 (fr) 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
SE453394B (sv) * 1986-07-07 1988-02-01 Pharmacia Ab Forfarande for framstellning av sulfaterade polysackarider genom anvendning av ett reducerande medel for sulfateringsreaktionen
EP0285357A3 (en) 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Control of retroviruses
DK505588D0 (da) 1988-02-26 1988-09-09 Jesper Hamburger Middel og anvendelse af samme
IT1217458B (it) 1988-05-02 1990-03-22 Crinos Ind Farmacoriologica S Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche
JP2769584B2 (ja) * 1990-06-04 1998-06-25 参天製薬株式会社 局所投与用抗アレルギー剤
IT1247175B (it) 1991-04-19 1994-12-12 Fidia Spa Procedimento per la purificazione di acido ialuronico e frazione di acido ialuronico puro per uso oftalmico.
ES2149178T3 (es) 1991-08-16 2000-11-01 Miles A Galin Implante ocular para la camara anterior refractivo, recubierto con un medicamento.
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
DE69621528T2 (de) 1995-02-07 2003-01-16 Shiseido Co. Ltd., Tokio/Tokyo Anti-inflamatorische agenzien
GB2317182B (en) 1996-09-11 2000-11-01 Johnson & Johnson Medical Sulfated polysaccharides and uses thereof in medical treatment
JPH10195107A (ja) 1997-01-10 1998-07-28 Shiseido Co Ltd オリゴ硫酸化ヒアルロン酸
DK0971961T3 (da) * 1997-04-04 2003-03-24 Fidia Advanced Biopolymers Srl N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling
US5981509A (en) 1997-05-20 1999-11-09 Shiseido Company, Ltd. Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide
IT1293484B1 (it) 1997-06-11 1999-03-01 Fidia Advanced Biopolymers Srl Materiale biologico comprendente una efficiente coltura di cellule e una matrice tridimensionale biocompatibile e biodegradabile
IT1294797B1 (it) 1997-07-28 1999-04-15 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante
ITPD980037A1 (it) 1998-02-25 1999-08-25 Fidia Advanced Biopolymers Srl Acido ialuronico solfatato e i suoi derivati legati covalentemente a polimeri sintetici pe la preparazione di biomateriali e per il rivesti
DE19813234A1 (de) 1998-03-26 1999-09-30 Knoell Hans Forschung Ev Verfahren zur Herstellung hochsulfatierter Hyaluronsäuren
JPH11279042A (ja) 1998-03-30 1999-10-12 Shiseido Co Ltd 皮膚外用剤
US6984667B2 (en) 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
ITPD980149A1 (it) 1998-06-17 1999-12-17 Fidia Advanced Biopolymers Srl Protesi tridimensionali comprendenti derivati dell'acido ialuronico per riparare o ricostruire i tessuti danneggiati e processo per la
US6492503B1 (en) 1998-07-31 2002-12-10 Seikagaku Corporation Glycosaminoglycan and drug compositions containing the same
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
IT1306644B1 (it) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico.
US6288043B1 (en) 1999-06-18 2001-09-11 Orquest, Inc. Injectable hyaluronate-sulfated polysaccharide conjugates
JP2001097997A (ja) 1999-10-01 2001-04-10 Shiseido Co Ltd 硫酸化ヒアルロン酸を用いたアフィニティー吸着担体及びその使用
JP4139029B2 (ja) * 1999-12-10 2008-08-27 大阪瓦斯株式会社 電源装置
JP2001163789A (ja) 1999-12-13 2001-06-19 Maruho Co Ltd マトリックスメタロプロテアーゼ阻害用医薬組成物
EP1471870B1 (en) 2000-01-10 2014-08-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US6828308B2 (en) * 2000-07-28 2004-12-07 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation
IT1317359B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e
DE10053053A1 (de) 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
ITPD20020064A1 (it) 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem
WO2003086474A2 (en) 2002-04-11 2003-10-23 Carbomer, Inc Fluorinated or paramagnetic alginate polymer, annexin paramagnetic conjugate, and their use as contrasting agent in mri
RU2005102604A (ru) 2002-07-03 2005-09-10 Перикор Сайенс, Инк. (Us) Композиция гиалуроновой кислоты и способы применения
JP2004262777A (ja) * 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
DE10352137A1 (de) 2003-11-04 2005-06-16 Beschorner, Katharina, Dr. Verwendung sulfatierter Hyaluronsäure
EP1694712A1 (en) 2003-12-04 2006-08-30 University of Utah Research Foundation Modified macromolecules and methods of making and using thereof
FR2864090B1 (fr) * 2003-12-19 2006-01-27 Aventis Pharma Sa Derives carboxy-reduits de l'acide hyaluronique, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
US20050203056A1 (en) 2003-12-19 2005-09-15 Aventis Pharma S.A. Carboxyl-reduced derivatives of hyaluronic acid, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them
ITPD20040245A1 (it) 2004-10-08 2005-01-08 Fidia Advanced Biopolymers Srl Biomateriali costituiti da acido ialuronico solfatato e gellano utilizzabili nella prevenzione delle adesioni spinali
DE102005004643B4 (de) 2005-01-28 2010-04-08 Innovent E.V. Technologieentwicklung Antivirale Kombinationen sowie ihre Verwendung
JP2006206849A (ja) 2005-01-31 2006-08-10 Seikagaku Kogyo Co Ltd アルキルエステル化されたグリコサミノグリカンの製造方法
US20090105463A1 (en) 2005-03-29 2009-04-23 Massachusetts Institute Of Technology Compositions of and Methods of Using Oversulfated Glycosaminoglycans
WO2006108022A1 (en) 2005-04-04 2006-10-12 Neoparin, Inc. Process for the induction of intramolecular migration of sulfates, phosphates, and other oxyanions
US7993678B2 (en) 2005-09-26 2011-08-09 Novozymes Biopolymer A/S Hyaluronic acid derivatives
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
US20080306022A1 (en) 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
DE602006019474D1 (de) 2005-11-22 2011-02-17 Ard Sa Hren dafür und verwendungen davon
US20070166266A1 (en) * 2006-01-19 2007-07-19 Solazyme, Inc. Methods and compositions for improving the health and appearance of skin
DK1994062T3 (da) 2006-03-02 2009-11-16 Novozymes Biopharma Dk As Aryl/alkyl-vinylsulfonhyaluronsyrederivater
ITPD20060219A1 (it) 2006-05-31 2007-12-01 Fidia Farmaceutici Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
US20080032920A1 (en) 2006-07-11 2008-02-07 Prestwich Glenn D Macromolecules modified with electrophilic groups and methods of making and using thereof
EP2070518A2 (en) 2006-07-25 2009-06-17 Osmotica Corp. Ophthalmic solutions
TW200838552A (en) 2007-01-25 2008-10-01 Novozymes Biopolymer As Methyl esters of hyaluronic acid
JP5088864B2 (ja) 2007-03-16 2012-12-05 オリンパス株式会社 生体組織補填材とその製造方法
EP2025687A1 (en) 2007-07-23 2009-02-18 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby
WO2009033047A2 (en) * 2007-09-07 2009-03-12 University Of Chicago Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan
EP2057983A1 (en) 2007-11-07 2009-05-13 Bruschettini S.r.l. Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations
US8093365B2 (en) * 2008-03-03 2012-01-10 New York University Biocompatible materials containing stable complexes method of TSG-6 and hyaluronan and method of using same
US8343942B2 (en) 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
AU2009231634B2 (en) 2008-04-04 2014-05-15 University Of Utah Research Foundation Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
BRPI1007325A2 (pt) 2009-02-02 2019-09-24 Otsuka Pharma Co Ltd "baixo peso molecular de polissulfatados derivados de ácido hialurônico e medicamentos que contenham o mesmo."
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
IT1393945B1 (it) 2009-04-21 2012-05-17 Fidia Farmaceutici Composizioni comprendenti acido ialuronico, acido ialuronico solfatato, calcio e vitamina d3 nel trattamento delle malattie osteoarticolari e muscoloscheletriche
IT1397246B1 (it) 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica
IT1397247B1 (it) 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
CA2830933A1 (en) 2011-03-23 2012-09-27 University Of Utah Research Foundation Methods for treating or preventing urological inflammation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199687A1 (en) * 2002-04-11 2003-10-23 Manssur Yalpani Biocompatible materials and probes
WO2007006403A2 (en) * 2005-07-07 2007-01-18 Fidia Advanced Biopolymers S.R.L. Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854134A (zh) * 2012-12-12 2015-08-19 索尔维特殊聚合物意大利有限公司 氟化壳聚糖衍生物
CN108350094A (zh) * 2015-11-16 2018-07-31 费迪亚医药股份公司 生产高纯度硫酸化ha的改进方法
CN111491641A (zh) * 2017-10-18 2020-08-04 格莱科米拉治疗公司 治疗慢性鼻窦炎的方法和组合物

Also Published As

Publication number Publication date
US8951990B2 (en) 2015-02-10
MX2010010904A (es) 2010-11-04
CA2719666C (en) 2016-08-16
AU2009231634B2 (en) 2014-05-15
CA2719666A1 (en) 2009-10-08
US20100317616A1 (en) 2010-12-16
EP2281008B1 (en) 2017-01-04
US7855187B1 (en) 2010-12-21
US20150209385A1 (en) 2015-07-30
KR20110004422A (ko) 2011-01-13
US8329673B2 (en) 2012-12-11
AU2009231634A1 (en) 2009-10-08
JP2011516672A (ja) 2011-05-26
US20120058161A1 (en) 2012-03-08
WO2009124266A3 (en) 2009-12-17
AU2009231634A2 (en) 2012-04-12
US9549945B2 (en) 2017-01-24
EP2281008A2 (en) 2011-02-09
US20130190234A1 (en) 2013-07-25
US8399430B2 (en) 2013-03-19
JP5758797B2 (ja) 2015-08-05
WO2009124266A2 (en) 2009-10-08
KR101594552B1 (ko) 2016-02-17
BRPI0909849A2 (pt) 2015-10-06
US20110082104A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
CN102177180A (zh) 烷基化半合成的糖胺聚糖醚及其制备和使用方法
JP6230909B2 (ja) 部分的および完全硫酸化ヒアルロナンの用途
KR870001901B1 (ko) 히알루론산 에스테르와 그 염의 제조방법
EP1835923B1 (en) Regimens for intra-articular viscosupplementation
TWI639434B (zh) 用於局部施用之包含玻尿酸和幾丁聚醣之黏膜黏性組成物
US10179147B2 (en) Applications of partially and fully sulfated hyaluronan
WO2001074400A1 (en) Transporters and drug delivery system by using the same
JP5636225B2 (ja) 炎症性腸疾患（ｉｂｄ）の治療及び予防に使用するための医薬組成物
EP1299083B1 (en) Implantable low molecular weight cellulosic compositions
HK1157800A (en) Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
LT4430B (lt) Akių lašai

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1157800

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110907

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1157800

Country of ref document: HK